# Duration of Dual Anti-Platelet Therapy (DUAL-ACS)

> **NCT03252249** · PHASE4 · COMPLETED · sponsor: **University of Edinburgh** · enrollment: 5094 (actual)

## Conditions studied

- Acute Coronary Syndrome
- Coronary Artery Disease

## Interventions

- **OTHER:** 3 months dual anti-platelet therapy
- **OTHER:** 12 months dual anti-platelet therapy

## Key facts

- **NCT ID:** NCT03252249
- **Lead sponsor:** University of Edinburgh
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-11
- **Primary completion:** 2023-02-04
- **Final completion:** 2023-02-04
- **Target enrollment:** 5094 (ACTUAL)
- **Last updated:** 2026-02-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03252249

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03252249, "Duration of Dual Anti-Platelet Therapy (DUAL-ACS)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03252249. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*